Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
Top Cited Papers
Open Access
- 23 July 2014
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 312 (4) , 353-361
- https://doi.org/10.1001/jama.2014.7734
Abstract
Up to 7 million persons worldwide are infected with both human immunodeficiency virus (HIV) and hepatitis C virus (HCV).1 Human immunodeficiency virus and HCV coinfection is associated with high rates of liver fibrosis, cirrhosis, hepatocellular carcinoma, and overall mortality.2 Coinfected patients who are cured of HCV have improved clinical outcomes and survival.3Keywords
This publication has 14 references indexed in Scilit:
- Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment CharacteristicsJAMA, 2013
- Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIVAnnals of Internal Medicine, 2013
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment OptionsNew England Journal of Medicine, 2013
- Sofosbuvir for Previously Untreated Chronic Hepatitis C InfectionNew England Journal of Medicine, 2013
- Current Management of Hepatitis C Virus Infection in Patients With HIV Co-infectionThe Journal of Infectious Diseases, 2013
- Pharmacokinetic Interactions Between the Hepatitis C Virus Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and LopinavirClinical Infectious Diseases, 2012
- PSI-7851, a Pronucleotide of β- d -2′-Deoxy-2′-Fluoro-2′- C -Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus ReplicationAntimicrobial Agents and Chemotherapy, 2010
- Viral hepatitis and HIV co-infectionAntiviral Research, 2009
- Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirinAIDS, 2008
- IN VITRO INHIBITION OF UDP GLUCURONOSYLTRANSFERASES BY ATAZANAVIR AND OTHER HIV PROTEASE INHIBITORS AND THE RELATIONSHIP OF THIS PROPERTY TO IN VIVO BILIRUBIN GLUCURONIDATIONDrug Metabolism and Disposition, 2005